Compare Stocks: CERC, DNTH, ERAS, and EWTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERC Cerecor	$14.41 -9.5%	$2.60	$1.98 ▼ $4.50	$1.38B	1.44	1.27 million shs	1.58 million shs
DNTH Dianthus Therapeutics	$96.81 -4.3%	$107.03	$32.22 ▼ $117.88	$5.53B	1.24	598,178 shs	2.83 million shs
ERAS Erasca	$14.77 -3.7%	$17.80	$1.75 ▼ $24.28	$5.37B	0.64	4.23 million shs	8.69 million shs
EWTX Edgewise Therapeutics	$45.32 -3.5%	$42.61	$14.09 ▼ $48.51	$5.10B	0.32	1.16 million shs	1.99 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERC Cerecor	0.00%	0.00%	0.00%	0.00%	+47.64%
DNTH Dianthus Therapeutics	-4.26%	-8.84%	-14.85%	+17.36%	+149.00%
ERAS Erasca	-3.72%	-6.99%	-18.26%	+8.05%	+784.43%
EWTX Edgewise Therapeutics	-3.45%	+2.07%	-2.41%	+22.91%	+226.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERC Cerecor	$14.41 -9.5%	$2.60	$1.98 ▼ $4.50	$1.38B	1.44	1.27 million shs	1.58 million shs
DNTH Dianthus Therapeutics	$96.81 -4.3%	$107.03	$32.22 ▼ $117.88	$5.53B	1.24	598,178 shs	2.83 million shs
ERAS Erasca	$14.77 -3.7%	$17.80	$1.75 ▼ $24.28	$5.37B	0.64	4.23 million shs	8.69 million shs
EWTX Edgewise Therapeutics	$45.32 -3.5%	$42.61	$14.09 ▼ $48.51	$5.10B	0.32	1.16 million shs	1.99 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERC Cerecor	0.00%	0.00%	0.00%	0.00%	+47.64%
DNTH Dianthus Therapeutics	-4.26%	-8.84%	-14.85%	+17.36%	+149.00%
ERAS Erasca	-3.72%	-6.99%	-18.26%	+8.05%	+784.43%
EWTX Edgewise Therapeutics	-3.45%	+2.07%	-2.41%	+22.91%	+226.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERC Cerecor	0.00	N/A	N/A	N/A
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$129.83	34.11% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	49.57% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	11.06% Upside

Current Analyst Ratings Breakdown

Latest CERC, DNTH, ERAS, and EWTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	DNTH Dianthus Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$135.00
9/8/2026	ERAS Erasca	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/4/2026	DNTH Dianthus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$156.00
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/14/2026	ERAS Erasca	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $20.00
8/13/2026	ERAS Erasca	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $21.00
8/12/2026	ERAS Erasca	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $22.00
8/11/2026	EWTX Edgewise Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$32.00 ➝ $36.00
8/6/2026	DNTH Dianthus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $128.00
8/6/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $158.00
8/5/2026	DNTH Dianthus Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$131.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERC Cerecor	$6.70M	206.49	N/A	N/A	$0.22 per share	65.50
DNTH Dianthus Therapeutics	$2.04M	2,594.41	N/A	N/A	$11.41 per share	8.48
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERC Cerecor	-$63.50M	-$0.57	N/A	N/A	N/A	-1,194.82%	-261.82%	-133.96%	N/A
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/5/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)

Latest CERC, DNTH, ERAS, and EWTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERC Cerecor	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERC Cerecor	0.79	2.19	2.18
DNTH Dianthus Therapeutics	N/A	26.10	26.10
ERAS Erasca	N/A	8.29	8.29
EWTX Edgewise Therapeutics	N/A	16.24	16.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERC Cerecor	62.84%
DNTH Dianthus Therapeutics	47.53%
ERAS Erasca	67.78%
EWTX Edgewise Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CERC Cerecor	45.70%
DNTH Dianthus Therapeutics	3.02%
ERAS Erasca	14.20%
EWTX Edgewise Therapeutics	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERC Cerecor	31	96.01 million	N/A	Not Optionable
DNTH Dianthus Therapeutics	92	54.67 million	53.02 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable

CERC, DNTH, ERAS, and EWTX Headlines

Recent News About These Companies

Biotech Options Buzz: UTHR, NMRA, EWTX

September 18 at 11:46 AM | schaeffersresearch.com

Investors Buy High Volume of Call Options on Edgewise Therapeutics (NASDAQ:EWTX)

September 18 at 11:20 AM | marketbeat.com

Edgewise Therapeutics (NASDAQ:EWTX) Hits New 52-Week High - Here's Why

September 17 at 1:39 PM | marketbeat.com

91,638 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Hsbc Holdings PLC

September 11, 2026 | marketbeat.com

First Light Asset Management LLC Purchases 93,325 Shares of Edgewise Therapeutics, Inc. $EWTX

September 10, 2026 | marketbeat.com

Legal & General Group Plc Takes Position in Edgewise Therapeutics, Inc. $EWTX

September 7, 2026 | marketbeat.com

Edgewise Therapeutics (NASDAQ:EWTX) Upgraded by Wall Street Zen to Hold Rating

September 5, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Acquires New Position in Edgewise Therapeutics, Inc. $EWTX

September 4, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Edgewise Therapeutics (EWTX)

September 3, 2026 | theglobeandmail.com

Braidwell LP Sells 350,618 Shares of Edgewise Therapeutics, Inc. $EWTX

September 3, 2026 | marketbeat.com

212,347 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Bank of New York Mellon Corp

September 3, 2026 | marketbeat.com

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 3, 2026 | marketbeat.com

Goldman Sachs Sticks to Their Hold Rating for Edgewise Therapeutics (EWTX)

September 2, 2026 | theglobeandmail.com

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

September 2, 2026 | prnewswire.com

Hsbc Holdings PLC Purchases New Shares in Edgewise Therapeutics, Inc. $EWTX

August 30, 2026 | marketbeat.com

Jefferies Financial Group Inc. Purchases Shares of 71,389 Edgewise Therapeutics, Inc. $EWTX

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Acquires New Stake in Edgewise Therapeutics, Inc. $EWTX

August 27, 2026 | marketbeat.com

6,606,336 Shares in Edgewise Therapeutics, Inc. $EWTX Purchased by BlackRock Inc.

August 27, 2026 | marketbeat.com

Artia Global Partners LP Takes Position in Edgewise Therapeutics, Inc. $EWTX

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Edgewise Therapeutics, Inc. $EWTX

August 26, 2026 | marketbeat.com

577,036 Shares in Edgewise Therapeutics, Inc. $EWTX Bought by Parkman Healthcare Partners LLC

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERC, DNTH, ERAS, and EWTX Company Descriptions

Cerecor NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Dianthus Therapeutics NASDAQ:DNTH

$96.81 -4.31 (-4.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$96.82 +0.02 (+0.02%)

As of 09/18/2026 07:30 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Erasca NASDAQ:ERAS

$14.77 -0.57 (-3.72%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.84 +0.07 (+0.44%)

As of 09/18/2026 07:30 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Edgewise Therapeutics NASDAQ:EWTX

$45.32 -1.62 (-3.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$44.85 -0.47 (-1.04%)

As of 09/18/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CERC, DNTH, ERAS, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CERC, DNTH, ERAS, and EWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CERC, DNTH, ERAS, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERC, DNTH, ERAS, and EWTX Company Descriptions

Cerecor NASDAQ:CERC

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Edgewise Therapeutics NASDAQ:EWTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CERC, DNTH, ERAS, and EWTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CERC, DNTH, ERAS, and EWTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CERC, DNTH, ERAS, and EWTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERC, DNTH, ERAS, and EWTX Company Descriptions

Cerecor NASDAQ:CERC

Dianthus Therapeutics NASDAQ:DNTH

Erasca NASDAQ:ERAS

Edgewise Therapeutics NASDAQ:EWTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools